ABSTRACT
BACKGROUND: Non-Hodgkin's lymphomas (NHL) originated in the otorhinolaryngological (ORL) area are rare diseases and its therapy is poorly established. METHODS: The diagnostic features, treatment and outcome based on therapy of 34 NHLs originated in the ORL area and seen in the Oncology Service from the Hospital de la Santa Creu i Sant Pau during a ten year period were reviewed. RESULTS: The predominant primary localization was the tonsil (17 patients), followed by rhinopharynx (8), massive involvement of Waldeyer's ring (4), and oropharynx, maxillary sinus and larynx in the remaining cases. In 26 patients the diagnosis was high-grade lymphoma. The stage distribution was 8 patients (24%) in stage I, 16 in stage II (47%), 3 in stage III (9%), and 5 in stage IV (16%). The treatment was heterogeneous and consisted in chemotherapy in 29 patients (38%), radiotherapy in 5 (15%) or the combination of both in 16 (47%). Eleven patients relapsed (38%), more commonly those treated with radiotherapy. The specific actuarial survival was 69%. CONCLUSIONS: NHL originated in the ORL area are uncommon neoplastic diseases, with a commonly dramatic response to chemotherapy. This should be the initial therapeutic modality in all cases.
Subject(s)
Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/radiotherapy , Otorhinolaryngologic Neoplasms/drug therapy , Otorhinolaryngologic Neoplasms/radiotherapy , Adult , Aged , Chemotherapy, Adjuvant , Female , Humans , Lymphoma, Non-Hodgkin/diagnosis , Male , Middle Aged , Otorhinolaryngologic Neoplasms/diagnosis , Survival AnalysisABSTRACT
The present Phase II study's main objective was to evaluate the rate of complete responses (CR) obtained through total androgenic suppression (TAS) in patients with disseminated prostate carcinoma. Twenty consecutive patients were recruited of which 19 were evaluable for response and toxicity. Treatment consisted in an association of orchiectomy or the analogous LH-RH Buselerin with the antiandrogenic Flutamide. There was 1 CR (5%) and 17 partial responses (PR). Sixteen patients with symptomatic disease had subjective improvement, usually during the first month of treatment. After an average follow-up of 20 months (range 7-29), 1 patient remains CR and 7 have regressed following PR, 4 of which have died. Tolerance was good, and side effects secondary to hypoandrogenism were frequent, although mild, requiring treatment discontinuation in 1 case. It is concluded that TAS is an excellent palliative approach in disseminated prostate carcinoma though the rate of CRs obtained is sensibly lower to that reported by Labrie (28.3%) and in the range of 0-8% achieved in most studies. It is questionable whether it will become standard therapy for metastatic prostate carcinoma.
Subject(s)
Buserelin/therapeutic use , Flutamide/therapeutic use , Orchiectomy , Prostatic Neoplasms/therapy , Acid Phosphatase/blood , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols , Buserelin/adverse effects , Combined Modality Therapy , Drug Evaluation , Flutamide/adverse effects , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Remission InductionABSTRACT
Seventy-two patients with advanced ovarian cancer received CAP chemotherapy followed by laparotomy and 'second-effort' surgery. The overall response to CAP therapy was 80%. A complete pathological response (CPR) was obtained in 16 patients and partial microscopic (PMiR) and macroscopic responses in 7 and 33 cases, respectively. The actuarial survival for the entire group was 36% at 50 months with a median survival of 34 months. No significant differences in survival between the CPR and PMiR groups were found. Radical second-effort surgery showed a somewhat beneficial effect. The tumor size before chemotherapy (less than 5 cm) and FIGO stage III had a significantly favorable effect on response rate and survival.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/therapy , Adult , Aged , Cisplatin/adverse effects , Cisplatin/therapeutic use , Combined Modality Therapy , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Female , Humans , Laparotomy , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , Survival RateABSTRACT
Because of the clinical activity of carboplatin in several types of tumors, this drug was studied in a phase II trial of 25 patients with advanced head and neck cancer [stage IV (M0)] without prior treatment. Six patients (24%) achieved objective response, including two patients with complete response. Carboplatin toxicity was mild in most patients, with nausea, vomiting, and myelosuppression being the most frequent side effects. No renal or neurologic toxicity was observed. Further trials of carboplatin in advanced head and neck cancer are warranted.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Organoplatinum Compounds/therapeutic use , Adult , Aged , Antineoplastic Agents/adverse effects , Carboplatin , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/pathology , Clinical Trials as Topic , Drug Evaluation , Head and Neck Neoplasms/blood , Head and Neck Neoplasms/pathology , Hematologic Diseases/chemically induced , Humans , Middle Aged , Neoplasm Staging , Organoplatinum Compounds/adverse effectsABSTRACT
The protocole of multidisciplinary therapy of the tongue and base of the tongue tumors in the "Hospital de la Sta. Creu i Sant Pau" is presented. The exposition of the management trends by surgery, radiotherapy and chemotherapy, in our protocole, is followed by the review of the therapeutic indications with special enphasis in the topographic ones in order to plan the surgical treatment. The non advanced tumors will be as well treated by intersticial radiotherapy as by surgery. In the treatment of the advanced tumors the multidisciplinary managament results essential. Depending on the degree of invasion, the topography of the tumor and the outline of therapeutic trials, the therapy will be chosen.
Subject(s)
Tongue Neoplasms/therapy , Combined Modality Therapy , France , Humans , Mandible/surgery , Methods , Neoplasm Staging , Tongue Neoplasms/mortality , Tongue Neoplasms/surgeryABSTRACT
A combination of hormonal therapy and chemotherapy (diethyl-estilbestrol or orchiectomy plus cyclophosphamide) was administered to 14 patients with histologic proof of untreated stage D prostatic adenocarcinoma with poor prognosis. Objective responses were obtained in 11 out of the 14 patients (78%), two of which were considered as complete regressions (14%). Response duration lasted for a mean of 9.5 months and the survival reached a mean of 14 months. The authors feel that is worth-while to treat very advanced cases of prostatic carcinoma with hormonal therapy and chemotherapy association.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Prostatic Neoplasms/drug therapy , Adenocarcinoma/pathology , Aged , Cyclophosphamide/administration & dosage , Diethylstilbestrol/administration & dosage , Humans , Male , Middle Aged , Prognosis , Prostatic Neoplasms/pathologyABSTRACT
The authors describe the results of cranial radiotherapy in 22 patients with brain metastases due to mammary cancer; 77.5% of the patients responded to treatment, 45.5% showing a complete response. The mean survival attained was 6.4 months for all the patients and 18 months for those with complete response. The presence of cerebellar metastases makes worse the prognosis.
Subject(s)
Brain Neoplasms/secondary , Breast Neoplasms , Adult , Aged , Bone Neoplasms/secondary , Brain/pathology , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Breast Neoplasms/pathology , Evaluation Studies as Topic , Female , Humans , Lung Neoplasms/secondary , Middle Aged , PrognosisABSTRACT
We have studied dermatoglyphic traits in a group of breast cancer patients. Comparison with a control group demonstrated that it is possible to delineate a high-risk group for the breast carcinoma through certain characteristic patterns of the surface markings of the hands.